Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Silke Gillessen¹, Alberto Bossi², Ian D Davis³, Johann de Bono⁴, Karim Fizazi⁵, Nicholas D James⁶, Nicolas Mottet⁷, Neal Shore⁸, Eric Small⁹, Mathew Smith¹⁰, Christopher Sweeney¹¹, Bertrand Tombal¹², Emmanuel S Antonarakis¹³, Ana M Aparicio¹⁴, Andrew J Armstrong¹⁵, Gerhardt Attard¹⁶, Tomasz M Beer¹⁷, Himisha Beltran¹⁸, Anders Bjartell¹⁹, Pierre Blanchard²⁰, Alberto Briganti²¹, Rob G Bristow²², Muhammad Bulbul²³, Orazio Caffo²⁴, Daniel Castellano²⁵, Elena Castro²⁶, Heather H Cheng²⁷, Kim N Chi²⁸, Simon Chowdhury²⁹, Caroline S Clarke³⁰, Noel Clarke³¹, Gedske Daugaard³², Maria De Santis³³, Ignacio Duran³⁴, Ros Eeles³⁵, Eleni Efstathiou³⁶, Jason Efstathiou³⁷, Onyeanunam Ngozi Ekeke³⁸, Christopher P Evans³⁹, Stefano Fanti⁴⁰, Felix Y Feng⁴¹, Valerie Fonteyne⁴², Nicola Fossati⁴³, Mark Frydenberg⁴⁴, Daniel George⁴⁵, Martin Gleave⁴⁶, Gwenaelle Gravis⁴⁷, Susan Halabi⁴⁸, Daniel Heinrich⁴⁹, Ken Herrmann⁵⁰, Celestia Higano⁵¹, Michael S Hofman⁵², Lisa G Horvath⁵³, Maha Hussain⁵⁴, Barbara Alicja Jereczek-Fossa⁵⁵, Robert Jones⁵⁶, Ravindran Kanesvaran⁵⁷, Pirkko-Liisa Kellokumpu-Lehtinen⁵⁸, Raja B Khauli⁵⁹, Laurence Klotz⁶⁰, Gero Kramer⁶¹, Raya Leibowitz⁶², Christopher J Logothetis⁶³, Brandon A Mahal⁶⁴, Fernando Maluf⁶⁵, Joaquin Mateo⁶⁶, David Matheson⁶⁷, Niven Mehra⁶⁸, Axel Merseburger⁶⁹, Alicia K Morgans¹⁸, Michael J Morris⁷⁰, Hind Mrabti⁷¹, Deborah Mukherji⁷², Declan G Murphy⁷³, Vedang Murthy⁷⁴, Paul L Nguyen⁷⁵, William K Oh⁷⁶, Piet Ost⁷⁷, Joe M O'Sullivan⁷⁸, Anwar R Padhani⁷⁹, Carmel Pezaro⁸⁰, Darren M C Poon⁸¹, Colin C Pritchard⁸², Danny M Rabah⁸³, Dana Rathkopf⁷⁰, Robert E Reiter⁸⁴, Mark A Rubin⁸⁵, Charles J Ryan¹³, Fred Saad⁸⁶, Juan Pablo Sade⁸⁷, Oliver A Sartor⁸⁸, Howard I Scher⁸⁹, Nima Sharifi⁹⁰, Iwona Skoneczna⁹¹, Howard Soule⁹², Daniel E Spratt⁹³, Sandy Srinivas⁹⁴, Cora N Sternberg⁹⁵, Thomas Steuber⁹⁶, Hiroyoshi Suzuki⁹⁷, Matthew R Sydes⁹⁸, Mary-Ellen Taplin¹¹, Derya Tilki⁹⁹, Levent Türkeri¹⁰⁰, Fabio Turco¹⁰¹, Hiroji Uemura¹⁰², Hirotsugu Uemura¹⁰³, Yüksel Ürün¹⁰⁴, Claire L Vale¹⁰⁵, Inge van Oort¹⁰⁶, Neha Vapiwala¹⁰⁷, Jochen Walz¹⁰⁸, Kosj Yamoah¹⁰⁹, Dingwei Ye¹¹⁰, Evan Y Yu¹¹¹, Almudena Zapatero¹¹², Thomas Zilli¹¹³, Aurelius Omlin¹¹⁴

Affiliations

¹ Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: silke.gillessen@eoc.ch.
² Genitourinary Oncology, Prostate Brachytherapy Unit, Gustave Roussy, Paris, France.
³ Monash University and Eastern Health, Victoria, Australia.
⁴ The Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK.
⁵ Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
⁶ The Institute of Cancer Research, London, UK.
⁷ University Jean Monnet, St Etienne, France.
⁸ Carolina Urologic Research Center, Myrtle Beach, SC, USA; Urology/Surgical Oncology, GenesisCare, Myrtle Beach, SC, USA.
⁹ UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
¹⁰ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
¹² Cliniques universitaires Saint Luc, Brussels, Belgium.
¹³ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
¹⁴ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁵ Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
¹⁶ University College London Cancer Institute, London, UK.
¹⁷ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
¹⁸ Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
¹⁹ Department of Urology, Skåne University Hospital, Malmö, Sweden.
²⁰ Département de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
²¹ Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
²² Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK.
²³ Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
²⁴ Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
²⁵ Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
²⁶ Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.
²⁷ Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
²⁸ BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
²⁹ Guys and St Thomas's NHS Foundation Trust, London, UK.
³⁰ Research Department of Primary Care & Population Health, Royal Free Campus, University College London, London, UK.
³¹ The Christie and Salford Royal Hospitals, Manchester, UK.
³² Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
³³ Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
³⁴ Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
³⁵ The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
³⁶ Houston Methodist Cancer Center, Houston, TX, USA.
³⁷ Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
³⁸ Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria.
³⁹ University of California Davis School of Medicine, Sacramento, CA, USA.
⁴⁰ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
⁴¹ University of California San Francisco, San Francisco, CA, USA.
⁴² Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium.
⁴³ Department of Urology, Ospedale Regionale di Lugano, Civico USI - Università della Svizzera Italiana, Lugano, Switzerland.
⁴⁴ Department of Surgery, Prostate Cancer Research Program, Monash University, Melbourne, Australia; Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia.
⁴⁵ Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA; Department of Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
⁴⁶ Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
⁴⁷ Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France.
⁴⁸ Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
⁴⁹ Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
⁵⁰ Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
⁵¹ University of British Columbia, Vancouver, British Columbia, Canada.
⁵² Prostate Cancer Theranostics and Imaging Centre of Excellence, Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
⁵³ Chris O'Brien Lifehouse, Camperdown, NSW, Australia; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia.
⁵⁴ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
⁵⁵ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
⁵⁶ School of Cancer Sciences, University of Glasgow, Glasgow, UK.
⁵⁷ Division of Medical Oncology, National Cancer Centre, Singapore.
⁵⁸ Faculty of Medicine and Health Technology, Tampere University and Tampere Cancer Center, Tampere, Finland; Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland.
⁵⁹ Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon.
⁶⁰ Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
⁶¹ Department of Urology, Medical University of Vienna, Vienna, Austria.
⁶² Oncology Institute, Shamir Medical Center, Be'er Ya'akov, Israel; Faculty of Medicine, Tel-Aviv University, Israel.
⁶³ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; University of Athens Alexandra Hospital, Athens, Greece.
⁶⁴ Department of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, USA.
⁶⁵ Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brasil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
⁶⁶ Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
⁶⁷ Faculty of Education, Health and Wellbeing, Walsall Campus, Walsall, UK.
⁶⁸ Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁶⁹ Department of Urology, University Hospital Schleswig-Holstein, Luebeck, Germany.
⁷⁰ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷¹ National Institute of Oncology, Mohamed V University, Rabat, Morocco.
⁷² Clemenceau Medical Center, Dubai, United Arab Emirates; Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
⁷³ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
⁷⁴ Tata Memorial Centre, Mumbai, India.
⁷⁵ Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁷⁶ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
⁷⁷ Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
⁷⁸ Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland.
⁷⁹ Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK.
⁸⁰ Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
⁸¹ Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong; The Chinese University of Hong Kong, Shatin, Hong Kong.
⁸² Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
⁸³ Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Urology, KFSHRC, Riyadh, Saudi Arabia.
⁸⁴ University of California Los Angeles, Los Angeles, CA, USA.
⁸⁵ Bern Center for Precision Medicine and Department for Biomedical Research, Bern, Switzerland.
⁸⁶ Centre Hospitalier de Université de Montréal, Montreal, Quebec, Canada.
⁸⁷ Instituto Alexander Fleming, Buenos Aires, Argentina.
⁸⁸ Tulane Cancer Center, New Orleans, LA, USA.
⁸⁹ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
⁹⁰ Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; Department of Cancer Biology, GU Malignancies Research Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.
⁹¹ Rafal Masztak Grochowski Hospital, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
⁹² Prostate Cancer Foundation, Santa Monica, CA, USA.
⁹³ University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁹⁴ Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA.
⁹⁵ Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA.
⁹⁶ Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
⁹⁷ Toho University Sakura Medical Center, Chiba, Japan.
⁹⁸ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
⁹⁹ Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.
¹⁰⁰ Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey.
¹⁰¹ Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.
¹⁰² Yokohama City University Medical Center, Yokohama, Japan.
¹⁰³ Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
¹⁰⁴ Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey; Ankara University Cancer Research Institute, Ankara, Turkey.
¹⁰⁵ University College London, MRC Clinical Trials Unit at UCL, London, UK.
¹⁰⁶ Radboud University Medical Center, Nijmegen, The Netherlands.
¹⁰⁷ Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰⁸ Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.
¹⁰⁹ Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA.
¹¹⁰ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
¹¹¹ Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA.
¹¹² Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain.
¹¹³ Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
¹¹⁴ Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Switzerland.

PMID: 36494221
PMCID: PMC7614721
DOI: 10.1016/j.eururo.2022.11.002

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Silke Gillessen et al. Eur Urol. 2023 Mar.

. 2023 Mar;83(3):267-293.

doi: 10.1016/j.eururo.2022.11.002. Epub 2022 Dec 6.

Authors

Affiliations

¹ Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: silke.gillessen@eoc.ch.
² Genitourinary Oncology, Prostate Brachytherapy Unit, Gustave Roussy, Paris, France.
³ Monash University and Eastern Health, Victoria, Australia.
⁴ The Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK.
⁵ Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
⁶ The Institute of Cancer Research, London, UK.
⁷ University Jean Monnet, St Etienne, France.
⁸ Carolina Urologic Research Center, Myrtle Beach, SC, USA; Urology/Surgical Oncology, GenesisCare, Myrtle Beach, SC, USA.
⁹ UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
¹⁰ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
¹² Cliniques universitaires Saint Luc, Brussels, Belgium.
¹³ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
¹⁴ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁵ Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
¹⁶ University College London Cancer Institute, London, UK.
¹⁷ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
¹⁸ Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
¹⁹ Department of Urology, Skåne University Hospital, Malmö, Sweden.
²⁰ Département de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
²¹ Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
²² Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK.
²³ Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
²⁴ Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
²⁵ Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
²⁶ Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.
²⁷ Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
²⁸ BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
²⁹ Guys and St Thomas's NHS Foundation Trust, London, UK.
³⁰ Research Department of Primary Care & Population Health, Royal Free Campus, University College London, London, UK.
³¹ The Christie and Salford Royal Hospitals, Manchester, UK.
³² Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
³³ Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
³⁴ Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
³⁵ The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
³⁶ Houston Methodist Cancer Center, Houston, TX, USA.
³⁷ Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
³⁸ Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria.
³⁹ University of California Davis School of Medicine, Sacramento, CA, USA.
⁴⁰ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
⁴¹ University of California San Francisco, San Francisco, CA, USA.
⁴² Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium.
⁴³ Department of Urology, Ospedale Regionale di Lugano, Civico USI - Università della Svizzera Italiana, Lugano, Switzerland.
⁴⁴ Department of Surgery, Prostate Cancer Research Program, Monash University, Melbourne, Australia; Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia.
⁴⁵ Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA; Department of Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
⁴⁶ Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
⁴⁷ Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France.
⁴⁸ Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
⁴⁹ Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
⁵⁰ Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
⁵¹ University of British Columbia, Vancouver, British Columbia, Canada.
⁵² Prostate Cancer Theranostics and Imaging Centre of Excellence, Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
⁵³ Chris O'Brien Lifehouse, Camperdown, NSW, Australia; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia.
⁵⁴ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
⁵⁵ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
⁵⁶ School of Cancer Sciences, University of Glasgow, Glasgow, UK.
⁵⁷ Division of Medical Oncology, National Cancer Centre, Singapore.
⁵⁸ Faculty of Medicine and Health Technology, Tampere University and Tampere Cancer Center, Tampere, Finland; Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland.
⁵⁹ Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon.
⁶⁰ Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
⁶¹ Department of Urology, Medical University of Vienna, Vienna, Austria.
⁶² Oncology Institute, Shamir Medical Center, Be'er Ya'akov, Israel; Faculty of Medicine, Tel-Aviv University, Israel.
⁶³ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; University of Athens Alexandra Hospital, Athens, Greece.
⁶⁴ Department of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, USA.
⁶⁵ Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brasil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
⁶⁶ Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
⁶⁷ Faculty of Education, Health and Wellbeing, Walsall Campus, Walsall, UK.
⁶⁸ Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁶⁹ Department of Urology, University Hospital Schleswig-Holstein, Luebeck, Germany.
⁷⁰ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷¹ National Institute of Oncology, Mohamed V University, Rabat, Morocco.
⁷² Clemenceau Medical Center, Dubai, United Arab Emirates; Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
⁷³ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
⁷⁴ Tata Memorial Centre, Mumbai, India.
⁷⁵ Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁷⁶ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
⁷⁷ Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
⁷⁸ Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland.
⁷⁹ Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK.
⁸⁰ Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
⁸¹ Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong; The Chinese University of Hong Kong, Shatin, Hong Kong.
⁸² Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
⁸³ Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Urology, KFSHRC, Riyadh, Saudi Arabia.
⁸⁴ University of California Los Angeles, Los Angeles, CA, USA.
⁸⁵ Bern Center for Precision Medicine and Department for Biomedical Research, Bern, Switzerland.
⁸⁶ Centre Hospitalier de Université de Montréal, Montreal, Quebec, Canada.
⁸⁷ Instituto Alexander Fleming, Buenos Aires, Argentina.
⁸⁸ Tulane Cancer Center, New Orleans, LA, USA.
⁸⁹ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
⁹⁰ Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; Department of Cancer Biology, GU Malignancies Research Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.
⁹¹ Rafal Masztak Grochowski Hospital, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
⁹² Prostate Cancer Foundation, Santa Monica, CA, USA.
⁹³ University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁹⁴ Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA.
⁹⁵ Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA.
⁹⁶ Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
⁹⁷ Toho University Sakura Medical Center, Chiba, Japan.
⁹⁸ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
⁹⁹ Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.
¹⁰⁰ Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey.
¹⁰¹ Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.
¹⁰² Yokohama City University Medical Center, Yokohama, Japan.
¹⁰³ Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
¹⁰⁴ Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey; Ankara University Cancer Research Institute, Ankara, Turkey.
¹⁰⁵ University College London, MRC Clinical Trials Unit at UCL, London, UK.
¹⁰⁶ Radboud University Medical Center, Nijmegen, The Netherlands.
¹⁰⁷ Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰⁸ Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.
¹⁰⁹ Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA.
¹¹⁰ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
¹¹¹ Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA.
¹¹² Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain.
¹¹³ Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
¹¹⁴ Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Switzerland.

PMID: 36494221
PMCID: PMC7614721
DOI: 10.1016/j.eururo.2022.11.002

Abstract

Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management.

Objective: To present consensus voting results for select questions from APCCC 2022.

Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3.

Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement.

Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis.

Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

Patient summary: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.

Keywords: Adjuvant therapy; Biochemical recurrence; Hormonal treatment; Locally advanced prostate cancer; Next-generation imaging; Prostate cancer; Prostate-specific membrane antigen positron emission tomography imaging; Salvage radiation therapy; Salvage therapy; Side effects.

PubMed Disclaimer

References

1. Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589–604. - PMC - PubMed
1. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73:178–211. - PubMed
1. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77:508–47. - PubMed
1. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM. Staging of prostate cancer. Histopathology. 2012;60:87–117. - PubMed
1. Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines: prostate cancer, version 1.2023. 2022. [Accessed 16 September 2022]. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf .

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Affiliations

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical